

UDC: 54.057:547.587.51:547.789:615.281:678.476

DOI: 10.15587/2519-4852.2020.221701

SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 3-(2-*N*-(ARYL,ACYL)AMINO-5-METHYL-1,3-THIAZOL-4-YL)-2*H*-CHROMEN-2-ONES

S. Vlasov, S. Kovalenko, I. Orlenko, I. Zhuravel, K. Krolenko, V. Vlasov

*The aim of this work is to study methods of 3-(2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones preparation and their antimicrobial activity.*

Materials and methods. ¹H NMR spectra were recorded on Varian Mercury-200 (200 MHz), ¹³C NMR spectra were acquired on Bruker Avance 500 ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) in DMSO-*d*₆ and CDCl₃. LC-MS analysis of compounds was performed on an Agilent 1100 HPLC instrument with chemical ionization at atmospheric pressure (APCI). The study of antimicrobial activity of compounds was performed by agar well diffusion method. The docking studies were performed using Autodock Vina.

Results and discussion. The interaction of 3-(2-bromopropanoyl)-2*H*-chromen-2-ones with *N*-substituted thioureas produced novel derivatives of 3-(2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol-4-yl)chromen-2-ones. The study of antimicrobial activity of the obtained compounds allowed to identify active samples against *E. coli* and *P. aeruginosa* strains. Among the tested compounds, 8-methoxy-3-{2-[(2-methoxyphenyl)amino]-5-methyl-1,3-thiazol-4-yl}-2*H*-chromen-2-one showed higher activity than the reference drug Streptomycin against *E. coli* strain. Some compounds showed high activity against *P. aeruginosa*. Docking studies of the synthesized compounds indicated that they can bind in the active site to bacterial tRNA (guanine37-N1)-methyltransferase.

Conclusions. Novel derivatives of 2*H*-chromen-2-ones with 2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol moiety at the position 3 were obtained by the Hantzsch thiazole synthesis starting from 3-(2-bromopropanoyl)-2*H*-chromen-2-ones. Studies of antimicrobial activity allowed to identify new 2*H*-chromen-2-one derivatives as equipotent antimicrobial agents to the reference drug Streptomycin or even more potent. The docking studies revealed that the synthesized compounds may be inhibitors of tRNA (guanine37-N1)-methyltransferase, which is a crucial enzyme for survival of different bacteria, e.g. *P. aeruginosa* during stress conditions

Keywords: coumarin, thiazole, antimicrobials, alkyl-group, synthesis

Copyright © 2020, S. Vlasov, S. Kovalenko, I. Orlenko, I. Zhuravel, K. Krolenko, V. Vlasov.
This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0>).

1. Introduction

Coumarin (2*H*-chromen-2-one) is the part of many compounds with antimicrobial and antifungal activity [1–4]. The recent studies show that 2*H*-chromen-2-ones can reduce the bacterial biofilm formation for some strains of bacteria as the result making them less antibiotic resistant [5–8]. The results of drug design research also show promising antimicrobial effect of 3-(2-*N*-R-amino-1,3-thiazol-4-yl)-2*H*-chromen-2-ones [9–11].

These compounds in most cases are prepared by the Hantzsch thiazole synthesis method using the reaction of thiocarboxamides [10–12] with the widely known 3-(2-bromoacetyl)-2*H*-chromen-2-ones [13–15]. It is interesting that 3-propanoyl-2*H*-chromen-2-ones [16, 17] were already reported, but the data about their keto-fragment α -bromination, their application as intermediates for synthesis of 3-(2-*N*-R-amino-5-alkyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones as well as the data about their biological activity have not been published.

The aim of this work is to study methods of 3-(2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones preparation and investigate their antimicrobial activity.

2. Planning (methodology) of the research

In order to obtain the target 3-(2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones as the objects for further antimicrobial studies, the possibility of application of 3-(α -bromoacetyl)2*H*-chromen-2-ones bromination procedure for preparation of 3-(2-bromopropanoyl)-2*H*-chromen-2-ones form 3-propanoyl derivatives should have been studied. The scope and limitations of the Hantzsch thiazole synthesis using 3-(2-bromopropanoyl)-2*H*-chromen-2-ones and substituted thioureas should be experimentally investigated, the procedure improvement should be suggested if needed. The further antimicrobial activity screening was planned as well as its results' analysis with computational chemistry methods.

3. Materials and methods

Chemical experiments. ¹H NMR spectra were recorded on Varian Mercury-200 (200 MHz), ¹³C NMR spectra were acquired on Bruker Avance 500 ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) in DMSO-*d*₆ and CDCl₃. TMS was used as internal standard. LC-MS analysis of compounds was performed on an Agilent

3. Materials and methods

Chemical experiments. ^1H NMR spectra were recorded on Varian Mercury-200 (200 MHz), ^{13}C NMR spectra were acquired on Bruker Avance 500 ^1H NMR (500 MHz) and ^{13}C NMR (125 MHz) in $\text{DMSO-}d_6$ and CDCl_3 . TMS was used as internal standard. LC-MS analysis of compounds was performed on an Agilent 1100 HPLC instrument with diode array and mass-selective detectors (Agilent LC-MSD SL), Zorbax SB-C18 column (4.6×15 mm) with chemical ionization at atmospheric pressure (APCI). Elemental analysis was performed on a EuroVector EA-3000 instrument. Melting points were determined on a Kofler bench. All solvents and reagents were commercially available. A study of antimicrobial activity of compounds 4 was performed by agar well diffusion method [18, 19]. The concentration of microbial cells was determined by McFarland standard [20]; the value was 10^7 cells in 1 ml of the media. The 18-24 hours culture of microorganisms was used for tests. For the bacteria cultivation, Müller-Hinton agar was used and Sabouraud agar was applied for *C. albicans* cultivation. The compounds were tested as the DMSO solution (concentration 100 μg per mL); the volume of the solution was 0.3 mL (the same as Streptomycin). Each experiment was repeated thrice. The antibacterial activity was estimated by the growth inhibition zone diameter for each microorganism [18].

The docking studies were performed using Autodock Vina [21]. Docking studies were performed for flexible ligands and rigid models of proteins. Crystallographic data for tRNA (guanine37-N1)-methyltransferase (EC2.1.1.228; TrmD) (5ZHN) and its active sites was obtained from the Protein Data Bank [22].

3-Propanoyl-2H-chromen-2-ones were prepared according to the known methods [16, 17].

3-(2-Bromopropanoyl)-2H-chromen-2-ones (general method).

3-Propanoyl-2H-chromen-2-one **1** (0.1 mole) was dissolved in 160 ml of chloroform. The bromine solution (0.1 mole, 5.2 ml in 16 ml of chloroform) was added dropwise to the solution of **1** stirring at room temperature. The reaction mixture was stirred and slightly heated (to 40–50 °C) until hydrogen bromide evolution was complete and absorbed by 10 % water solution of NaOH. Then, 70 % of the solvent volume was evaporated and allowed to cool. Crystals, which were formed were collected by filtration and gently washed with small portions of chloroform and ethanol.

3-(2-Bromopropanoyl)-2H-chromen-2-one (2a). The compound was obtained in 85 % yield as a the yellow powder; ^1H NMR (500 MHz, CDCl_3): δ 1.88 (d, 3H, $J=6.5$ Hz, CH_3), 5.91 (q, 1H, $J=6.5$ Hz, CH), 7.33 - 7.45 (m, 2H, H Ar), 7.64 - 7.74 (m, 2H, H Ar), 8.59 (s, 1H, H-4); ^{13}C NMR (125 MHz, CDCl_3): δ 19.3, 45.9, 116.8, 118.2, 122.8, 125.1, 130.0, 134.6, 149.0, 155.2, 158.5, 191.7. LC-MS, m/z : 281 $[\text{M}+\text{H}]^+$. Mp 153 – 155 °C. Anal. Calcd for $\text{C}_{12}\text{H}_9\text{BrO}_3$: C, 51.27; H, 3.23. Found: C, 51.43; H, 3.35.

3-(2-Bromopropanoyl)-8-methoxy-2H-chromen-2-one (2b). The compound was obtained in 76 % yield as a the yellow powder; ^1H NMR (500 MHz, CDCl_3): δ 1.85 (d, 3H, $J=6.5$ Hz, CH_3), 5.95 (q, 1H, $J=6.5$ Hz, CH), 7.17 - 7.31 (m, 3H, H Ar), 8.55 (s, 1H, H-4); ^{13}C NMR (125 MHz, CDCl_3): δ 19.3, 45.9, 56.3, 116.1, 118.8, 121.1, 123.0, 125.0, 144.8, 147.1, 149.1, 158.0, 191.8. LC-MS, m/z : 312 $[\text{M}+\text{H}]^+$. Mp 110 – 112 °C. Anal. Calcd for $\text{C}_{13}\text{H}_{11}\text{BrO}_4$: C, 50.19; H, 3.56. Found: C, 50.37; H, 3.60.

3-(2-N-R-amino-5-alkyl-1,3-thiazol-4-yl)-2H-chromen-2-ones 4 (general method). To the solution of 3-(2-bromopropanoyl)-2H-chromen-2-one **2** (1 mmole) in the minimal amount of 2-propanol, the solution of thiourea **3** (1 mmole) in the same solvent was added. Almost immediately after addition, the formation of clear solution was observed and after 4-10 minutes, the product precipitated. The mixture was additionally stirred at reflux for 1 hour and then cooled down to room temperature. The reaction mixture was neutralized with ammonium hydroxide solution. The precipitate was collected by filtration and dried.

3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one (4a). The compound was obtained in 75 % yield as a the yellow powder; ^1H NMR (200 MHz, $\text{DMSO-}d_6$): δ 2.15 (s, 3H, CH_3), 6.85 (br. s, 2H, NH_2), 7.36 (t, 1H, $J=7.5$ Hz, H-8), 7.42 (d, 1H, $J=8.2$ Hz, H-6), 7.61 (t, 1H, $J=7.2$ Hz, H-7), 7.77 (d, 1H, $J=7.0$ Hz, H-5), 8.14 (s, 1H, H-4); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$): δ : 12.4, 116.4, 119.4, 119.5, 122.2, 125.1, 129.1, 132.4, 138.2, 143.3, 153.5, 159.0, 165.6. LC-MS, m/z : 259 $[\text{M}+\text{H}]^+$. Mp 216 – 218 °C. Anal. Calcd for $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}_2\text{S}$: C, 60.45; H, 3.90; N, 10.85. Found: C, 60.56; H, 4.05; N, 10.74.

3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-8-methoxy-2H-chromen-2-one (4b). The compound was obtained in 82 % yield as a the yellow powder; ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 2.17 (s, 3H, CH_3), 3.92 (s, 3H, OCH_3), 6.97 (br. s, 2H, NH_2), 7.27-7.33 (m, 3H, H Ar), 8.09 (s, 1H, H-4); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$): δ 11.9, 56.0, 114.0, 119.0, 119.5, 119.7, 122.4, 124.5, 138.7, 142.3, 142.7, 146.2, 158.2, 164.9. LC-MS, m/z : 289 $[\text{M}+\text{H}]^+$. Mp 205 – 207 °C. Anal. Calcd for $\text{C}_{14}\text{H}_{12}\text{N}_2\text{O}_3\text{S}$: C, 58.32; H, 4.20; N, 9.72. Found: C, 58.51; H, 4.14; N, 9.69.

N-[5-methyl-4-(2-oxo-2H-chromen-3-yl)-1,3-thiazol-2-yl]acetamide (4c). The compound was obtained in 86 % yield as a the yellow powder; ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 2.13 (s, 3H, CH_3), 2.32 (s, 3H, CH_3), 7.38 (t, 1H, $J=7.1$ Hz, H-8), 7.44 (d, 1H, $J=8.2$ Hz, H-6), 7.63 (t, 1H, $J=7.6$ Hz, H-7), 7.78 (d, 1H, $J=7.6$ Hz, H-5), 8.17 (s, 1H, H-4), 12.12 (br. s, 1H, NH); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$): δ 11.9, 22.8, 116.4, 119.4, 122.8, 125.1, 125.4, 129.1, 132.4, 139.4, 143.5, 153.6, 154.7, 159.0, 168.8. LC-MS, m/z : 301 $[\text{M}+\text{H}]^+$. Mp 257 – 258 °C. Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_3\text{S}$: C, 59.99; H, 4.03; N, 9.33. Found: C, 60.18; H, 4.22; N, 9.50.

***N*-[4-(8-methoxy-2-oxo-2*H*-chromen-3-yl)-5-methyl-1,3-thiazol-2-yl]acetamide (**4d**).** The compound was obtained in 91 % yield as a the yellow powder; ^1H NMR (400 MHz, DMSO- d_6): δ 2.15 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 3.97 (s, 3H, OCH₃), 7.24-7.35 (m, 3H, H Ar), 8.09 (s, 1H, H-4), 11.80 (br. s, 1H, NH); ^{13}C NMR (100 MHz, DMSO- d_6): δ 11.4, 22.3, 56.1, 114.2, 119.4, 119.7, 122.4, 124.5, 124.9, 138.9, 142.4, 143.2, 146.3, 154.3, 158.3, 168.3. LC-MS, m/z : 331 [M+H]⁺. Mp > 300°C. Anal. Calcd for C₁₆H₁₄N₂O₄S: C, 58.17; H, 4.27; N, 8.48. Found: C, 58.39; H, 4.45; N, 8.32.

8-Methoxy-3-[5-methyl-2-(phenylamino)-1,3-thiazol-4-yl]-2*H*-chromen-2-one (4e**).** The compound was obtained in 68 % yield as a the yellow powder; ^1H NMR (400 MHz, DMSO- d_6): δ 2.36 (s, 3H, CH₃), 3.93 (s, 3H, OCH₃), 7.63 (t, 1H, $J=7.2$ Hz, H-4'), 7.24-7.35 (m, 5H, H Ar), 7.59 (d, 2H, $J=7.7$ Hz, H-2',6'), 8.20 (s, 1H, H-4), 10.07 (br. s, 1H, NH); ^{13}C NMR (100 MHz, DMSO- d_6): δ 12.2, 56.6, 114.6, 117.2, 120.0, 120.3, 121.0, 121.5, 123.1, 125.0, 129.4, 140.4, 141.6, 142.9, 143.6, 146.8, 158.8, 160.2. LC-MS, m/z : 365 [M+H]⁺. Mp 162 – 163°C. Anal. Calcd for C₂₀H₁₆N₂O₃S: C, 65.92; H, 4.43; N, 7.69. Found: C, 66.18; H, 4.55; N, 7.85.

8-Methoxy-3-{2-[(2-methoxyphenyl)amino]-5-methyl-1,3-thiazol-4-yl}-2*H*-chromen-2-one (4f**).** The compound was obtained in 65 % yield as a the yellow powder; ^1H NMR (400 MHz, DMSO- d_6): δ 2.24 (s, 3H, CH₃), 3.85 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 6.85 – 6.95 (m, 2H, H-3',5'), 6.99 (t, 1H, $J=6.5$ Hz, H-4'), 7.24-7.37 (m, 3H, H Ar), 8.19 (s, 1H, H-4), 8.30 (d, 1H, $J=7.5$

Hz, H-6'), 9.38 (br. s, 1H, NH); ^{13}C NMR (100 MHz, DMSO- d_6): δ 12.2, 56.1, 56.6, 111.3, 114.6, 118.6, 120.1, 120.3, 121.0, 121.5, 122.2, 123.2, 125.0, 130.6, 139.9, 142.9, 143.4, 146.8, 148.4, 158.8, 160.8. LC-MS, m/z : 395 [M+H]⁺. Mp 193 – 195 °C. Anal. Calcd for C₂₁H₁₈N₂O₄S: C, 63.95; H, 4.60; N, 7.10. Found: C, 64.23; H, 4.61; N, 7.29.

4. Results

The key intermediates – 3-(2-bromopropanoyl)-2*H*-chromen-2-ones **2** were prepared by bromination of the known 3-propanoyl-2*H*-chromen-2-ones **1** in order to synthesize novel 3-(2-*N*-R-amino-1,3-thiazol-4-yl)-2*H*-chromen-2-ones-derivatives and study their antimicrobial activity (Fig. 1). The obtained compounds **2** are crystalline solids. Their ^1H NMR spectra contain signals of CH₃CHBr- fragment as a doublet at 1.85-1.88 ppm and a quartet at 5.91-5.95 ppm with 6.5 Hz spin-spin coupling constant.

For construction of the thiazole cycle of 3-(2-*N*-R-amino-1,3-thiazol-4-yl)-2*H*-chromen-2-ones **3**, the reaction of **2** with substituted thioureas **3** was performed (Fig. 1). The synthesis was carried out in 2-propanol media at reflux. The target compounds **4** were isolated after the treatment of the reaction mixture with aqueous solution of ammonia. The obtained 3-(2-*N*-R-amino-5-alkyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones **4** in ^1H NMR spectra have the signals of amino-group protons in the region 6.85 – 6.97 ppm for the derivatives **4a,b** while for the aryl-substituted compounds **4d,f** the signal of NH-group is shifted downfield to 9.38 – 10.07 ppm and for the acetamides **4c,d** the NH-group signal is observed in the region 11.80 – 12.12 ppm.




Fig. 1. Synthesis of 3-(2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones: **1a** R=H; **1b** R=8-OCH₃; **2a** R=H; **2b** R=8-OCH₃; **3a** R¹=H; **3b** R¹=-COCH₃; **3c** R¹=Ph; **3d** R¹=2-(OCH₃)C₆H₄; **4a** R=H, R¹=H; **4b** R=8-OCH₃, R¹=H; **4c** R=H, R¹=-COCH₃; **4d** R=8-OCH₃, R¹=-COCH₃; **4e** R=8-OCH₃, R¹=Ph; **4f** R=8-OCH₃, R¹=2-(OCH₃)C₆H₄

The antimicrobial activity of the obtained compounds **4** was studied by agar well diffusion method using the standard strains of microorganisms [18]. It was found that compounds **4b**, **4c**, **4e** inhibit the growth of the *S. aureus* strain. As far as compounds **4b** and **4e** are concerned, they also inhibit growth of *E. coli*, but their activity is smaller than it is for the reference drug Streptomycin (Table 1).

The compounds **4b**, **4e** and **4f** showed similar activity against *P. aeruginosa*. The antimicrobial activity against the *E. coli* strain of the compound **4f** appeared

to be higher than the activity of the reference drug Streptomycin.

The obtained results of antimicrobial activity screening revealed the growth-inhibitory activity of the most of compounds **4** against the *P. aeruginosa* bacterial strain, which is known to be highly resistant for a variety of modern antibiotics. They do not have bactericidal activity for this microorganism which quickly adapts for a new antibiotic [23]. Therefore we decided to perform the computer docking study of the obtained compounds with the aim to see whether they could be selective inhib-

itors of tRNA (guanine37-N1)-methyltransferase (EC2.1.1.228; TrmD), which is known to be the crucial

enzyme for survival of bacterial (also *Pseudomonas aeruginosa*) at a moment of stress [24].

Table 1

The results of antimicrobial activity screening for compounds 4 (concentration 100 µg per mL)

Compd. number	Diameters of growth inhibition zones in mm,					
	<i>S. aureus</i> ATCC 25923	<i>E.coli</i> ATCC 25922	<i>P. vulgaris</i> ATCC 4636	<i>P. aeruginosa</i> ATCC 27853	<i>B. subtilis</i> ATCC 6633	<i>C. albicans</i> ATCC 653/885
4a	19, 19, 20	20, 19, 19	17, 16, 16	19, 19, 20	19, 18, 19	18, 17, 17
4b	24, 25, 25	23, 24, 23	20, 20, 19	23, 22, 22	20, 21, 22	22, 21, 21
4c	22, 23, 22	18, 19, 18	17, 16, 16	22, 20, 20	21, 21, 20	19, 19, 20
4d	18, 19, 19	17, 17, 18	16, 15, 17	20, 21, 21	20, 21, 21	17, 17, 17
4e	24, 24, 25	23, 24, 24	17, 16, 17	22, 23, 22	23, 23, 22	20, 18, 29
4f	19, 20, 19	27, 28, 27	17, 17, 17	23, 24, 23	19, 19, 20	17, 17, 16
Strept.*	30, 31, 29	24, 24, 25	25, 26, 24	25, 24, 25	27, 26, 25	14, 13, 14

* Streptomycin

Table 2

The results of the computer docking study of interaction of compounds 4 with the active site of PaTrmDc

Compd. number	affinity, kcal/mole	ligand binding with the active site (+/-) amino acids of the active site interacting with the ligand
4a	-7.4	+ PRO-94; TYR-120; VAL-142; ASP-178; GLY-179; LEU-180; LEU-181; ASP-182
4b	-6.7	+ PRO-94; ARG-119; TYR-120; VAL-142; LEU-143; GLY-145; ARG-159; ASP-178
4c	-8.1	+ PRO-94; GLN-95; TYR-120; VAL-142; LEU-143; GLN-101; ARG-105; ASP-178; GLY-179; LEU-180; LEU-181; ASP-182
4d	-8.0	+ PRO-94; TYR-120; ASP-140; TYR-141; ASP-178; GLY-179; LEU-180; ASP-182
4e	-8.9	+ PRO-94; GLN-95; TYR-120; VAL-142; GLN-101; ARG-159; ASP-178; GLY-179; LEU-181; ASP-182; HIS-185
4f	-9.1	+ TYR-91; PRO-94; GLN-95; ARG-119; TYR-120; GLY-122; TYR-141; VAL-142; GLY-179; LEU-180; LEU-181; ASP-182; LEU-228

The computer docking results for binding of compounds 4 with PaTrmDc in comparison with its known selective inhibitor showed that all of them are able to bind the active site of the enzyme (Table 2). On the other hand the decrease in polarity of the substituent at position 2 of the thiazole increases the affinity of the ligand towards the target.

5. Discussion

The previously reported results [10] show that the derivatives of 8-ethoxy-2H-chromen-2-one bearing the fragment of thiazole at position 3 can inhibit the growth of *B. bronchiseptica* ATCC 4617 and *B. pumilus* ATCC 14884 better than the reference drug Ampicillin. The promising antibacterial inhibitory concentrations were reported for the compounds with the similar structures bearing 5-methoxy-2H-chromen-2-one fragment and 2-bromophenylamino or 3,4-dichlorophenyl in 2-aminothiazole moiety (60-73 µM) [9]. The other paper

[11] presents the research where 3-(thiazol-4-yl)-2H-chromen-2-ones inhibited the growth of *S. aureus* ATCC 25923 and *H. influenzae* ATCC 10211 strains at higher level than Tetracycline and were even able to inhibit *M. tuberculosis* H37Rv ATCC 27294. Although the inhibitory concentration for the tested compounds was tenfold higher than those of Isoniazid.

The results of our chemical experiments show the successful bromination of 3-propanoyl-2H-chromen-2-ones, and also perfect results in the Hantzsch thiazole synthesis as the key-step for preparation of the novel target 3-(2-N-(aryl,acyl)amino-5-methyl-1,3-thiazol-4-yl)-2H-chromen-2-ones. Therefore, our research revealed the possibility of synthesis of 3-(thiazol-4-yl)-2H-chromen-2-ones' analogues with the methyl group at position 5 of thiazole. It has been also shown that the synthesized compounds can effectively inhibit the growth of *S. aureus* ATCC 25923, *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 and are also able to

show better inhibitory results than the reference drug Streptomycin.

The results of the docking studies of the target compounds as the ligands for bacterial tRNA (guanine37-N1)-methyltransferase obviously show that the introduction of the substituted phenyl substituents to amino-group of the thiazole moiety in the core 3-(2-amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-one is favourable for interaction with the enzyme. It also correlates with the results of agar-well diffusion screening results because the compounds 4e and 4f, which display promising docking results, also have the largest growth inhibition zones. Therefore, the docking modelling of interaction of the 3-(2-amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-one derivatives with tRNA (guanine37-N1)-methyltransferase could be useful at the stage of pre-screening filtration of virtual libraries of the compounds planned for further antimicrobial activity search.

Study limitations. As far as this research contains only primary screening results on the activity of 3-(2-amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones against the standard strains of microorganisms the clear obstacle for the research expand is the availability of the clinical strains of the corresponding bacteria.

Prospects for further research. The developed methods for synthesis of 3-(2-amino-5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones allow to vary the substituents in both heterocyclic fragments. Therefore, the promising strategy of the further investigation is the synthesis of the lead compounds identified after the preliminary screening of the virtual libraries of 3-(2-amino-

5-methyl-1,3-thiazol-4-yl)-2*H*-chromen-2-ones as to their ability to bind the active site of the bacterial tRNA (guanine37-N1)-methyltransferase.

6. Conclusions

By the Hantzsch thiazole synthesis, the derivatives of 2*H*-chromen-2-ones having the fragment of 2-*N*-(aryl,acyl)amino-5-methyl-1,3-thiazol at the position 3 were obtained. The study of antimicrobial activity of the synthesized compounds allowed for identification of the 2*H*-chromen-2-ones derivatives as compounds of similar of better activity than the reference drug Streptomycin. The docking studies revealed that the synthesized compound may be inhibitors of tRNA (guanine37-N1)-methyltransferase, which is a crucial enzyme for survival of different bacteria e.g. *P. aeruginosa* during stress conditions.

Conflict of interests

The authors declare that they have no conflict of interests.

Acknowledgement

The authors acknowledge Enamine Ltd. for the measurement of ¹³C NMR and LC-MS spectra of the obtained substances. Authors also acknowledge the Head of microorganism biochemistry and biotechnology laboratory of The Institute of microbiology and immunology named after I. I. Mechnikov NAMS of Ukraine, Dr. Tatyana P. Osolodchenko, for the antimicrobial activity test.

References

1. Singh, L. R., Avula, S. R., Raj, S., Srivastava, A., Palnati, G. R., Tripathi, C. K. M. et. al. (2017). Coumarin-benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation. *The Journal of Antibiotics*, 70 (9), 954–961. doi: <http://doi.org/10.1038/ja.2017.70>
2. Fotso, G. W., Ngameni, B., Storr, T. E., Ngadjui, B. T., Mafu, S., Stephenson, G. R. (2020). Synthesis of Novel Stilbene-Coumarin Derivatives and Antifungal Screening of Monotes kerstingii-Specialized Metabolites Against *Fusarium oxysporum*. *Antibiotics*, 9 (9), 537. doi: <http://doi.org/10.3390/antibiotics9090537>
3. Sanduja, M., Gupta, J., Singh, H., Pagare, P. P., Rana, A. (2020). Uracil-coumarin based hybrid molecules as potent anti-cancer and anti-bacterial agents. *Journal of Saudi Chemical Society*, 24 (2), 251–266. doi: <http://doi.org/10.1016/j.jscs.2019.12.001>
4. Mahmoud, M. R., El-Shahawi, M. M., Abu El-Azm, F. S., Abdeen, M. (2017). Synthesis and Antimicrobial Activity of Polyfunctionally Substituted Heterocyclic Compounds Derived from 5-Cinnamoylamino-2-Cyanomethyl-1,3,4-Thiadiazole. *Journal of Heterocyclic Chemistry*, 54 (4), 2352–2359. doi: <http://doi.org/10.1002/jhet.2824>
5. Reen, F. J., Gutiérrez-Barranquero, J. A., Parages, M. L., O'Gara, F. (2018). Coumarin: a novel player in microbial quorum sensing and biofilm formation inhibition. *Applied Microbiology and Biotechnology*, 102 (5), 2063–2073. doi: <http://doi.org/10.1007/s00253-018-8787-x>
6. Yang, L., Li, S., Qin, X., Jiang, G., Chen, J., Li, B. et. al. (2017). Exposure to Umbelliferone Reduces *Ralstonia solanacearum* Biofilm Formation, Transcription of Type III Secretion System Regulators and Effectors and Virulence on Tobacco. *Frontiers in Microbiology*, 8. doi: <http://doi.org/10.3389/fmicb.2017.01234>
7. Zhang, S., Liu, N., Liang, W., Han, Q., Zhang, W., Li, C. (2016). Quorum sensing-disrupting coumarin suppressing virulence phenotypes in *Vibrio splendidus*. *Applied Microbiology and Biotechnology*, 101 (8), 3371–3378. doi: <http://doi.org/10.1007/s00253-016-8009-3>
8. Ojima, Y., Nunogami, S., Taya, M. (2016). Antibiofilm effect of warfarin on biofilm formation of *Escherichia coli* promoted by antimicrobial treatment. *Journal of Global Antimicrobial Resistance*, 7, 102–105. doi: <http://doi.org/10.1016/j.jgar.2016.08.003>
9. Osman, H., Yusufzai, S. K., Khan, M. S., Abd Razik, B. M., Sulaiman, O., Mohamad, S. et. al. (2018). New thiazolyl-coumarin hybrids: Design, synthesis, characterization, X-ray crystal structure, antibacterial and antiviral evaluation. *Journal of Molecular Structure*, 1166, 147–154. doi: <http://doi.org/10.1016/j.molstruc.2018.04.031>
10. Arshad, A., Osman, H., Bagley, M. C., Lam, C. K., Mohamad, S., Zahariluddin, A. S. M. (2011). Synthesis and antimicrobial properties of some new thiazolyl coumarin derivatives. *European Journal of Medicinal Chemistry*, 46 (9), 3788–3794. doi: <http://doi.org/10.1016/j.ejmech.2011.05.044>
11. Mohamed, H. M., El-Wahab, A. H. F. A., Ahmed, K. A., El-Agrody, A. M., Bedair, A. H., Eid, F. A., Khafagy, M. M. (2012). Synthesis, Reactions and Antimicrobial Activities of 8-Ethoxycoumarin Derivatives. *Molecules*, 17 (1), 971–988. doi: <http://doi.org/10.3390/molecules17010971>
12. Zhuravel, I., Kovalenko, S., Vlasov, S., Chernykh, V. (2005). Solution-phase Synthesis of a Combinatorial Library of 3-[4-(Coumarin-3-yl)-1,3-thiazol-2-ylcarbamoyl]propanoic acid Amides. *Molecules*, 10 (2), 444–456. doi: <http://doi.org/10.3390/10020444>

13. KhanYusufzai, S., Osman, H., Khan, M. S., Mohamad, S., Sulaiman, O., Parumasivam, T. et. al. (2017). Design, characterization, in vitro antibacterial, antitubercular evaluation and structure–activity relationships of new hydrazinyl thiazolyl coumarin derivatives. *Medicinal Chemistry Research*, 26 (6), 1139–1148. doi: <http://doi.org/10.1007/s00044-017-1820-2>
14. Hamdi, M., Talhi, O., Silva, A., Lechani, N., Kheddis-Boutemur, B., Laichi, Y., Bachari, K. (2018). Synthetic Approach Toward Heterocyclic Hybrids of [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazines. *Synlett*, 29 (11), 1502–1504. doi: <http://doi.org/10.1055/s-0036-1591991>
15. Bag, S., Ghosh, S., Tulsan, R., Sood, A., Zhou, W., Schifone, C. et. al. (2013). Design, synthesis and biological activity of multifunctional α,β -unsaturated carbonyl scaffolds for Alzheimer's disease. *Bioorganic & Medicinal Chemistry Letters*, 23 (9), 2614–2618. doi: <http://doi.org/10.1016/j.bmcl.2013.02.103>
16. Banerjee, A., Santra, S. K., Mishra, A., Khatun, N., Patel, B. K. (2015). Copper(i)-promoted cycloalkylation–peroxidation of unactivated alkenes via sp³C–H functionalisation. *Organic & Biomolecular Chemistry*, 13 (5), 1307–1312. doi: <http://doi.org/10.1039/c4ob01962h>
17. Widman, O. (1918). Über eine neue Gruppe von Cyclopropan-Derivaten. I: Die Einwirkung von Phenyl-acylhalogeniden auf 3-Acidyl-cumarine bei Gegenwart von Natriumalkoholat. *Berichte Der Deutschen Chemischen Gesellschaft*, 51 (1), 533–541. doi: <http://doi.org/10.1002/cber.19180510165>
18. Coyle, M. B. (2005). *Manual of antimicrobial susceptibility testing*. Washington, 29–39.
19. Bacteriological Control of Growth Media (2001). Information Letter of the Ukraine Ministry of Health No. 05.4.1/1670. Kyiv.
20. McFarland, J. (1907). The nephelometer: an instrument for estimating the number of bacteria in suspensions used for calculating the opsonic index and for vaccines. *JAMA: The Journal of the American Medical Association*, 49 (14), 1176–1178. doi: <http://doi.org/10.1001/jama.1907.25320140022001f>
21. Trott, O., Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*, 31 (2), 455–461. doi: <http://doi.org/10.1002/jcc.21334>
22. Zhong, W., Pasunooti, K. K., Balamkundu, S., Wong, Y. W., Nah, Q., Liu, C. F. et. al. (2019). Crystal structure of TrmD from *Pseudomonas aeruginosa* in complex with active-site inhibitor. doi: <http://doi.org/10.2210/pdb5zhm/pdb>
23. Lazareva, A. V., Tchebotar, I. V., Kryzhanovskaya, O. A., Tchebotar, V. I., Mayanskiy, N. A. (2015). *Pseudomonas aeruginosa: Pathogenicity, Pathogenesis and Diseases*. *Clinical Microbiology and Antimicrobial Chemotherapy*, 17 (3), 170–186.
24. Zhong, W., Pasunooti, K. K., Balamkundu, S., Wong, Y. H., Nah, Q., Gadi, V. et. al. (2019). Thienopyrimidinone Derivatives That Inhibit Bacterial tRNA (Guanine37-N1)-Methyltransferase (TrmD) by Restructuring the Active Site with a Tyrosine-Flipping Mechanism. *Journal of Medicinal Chemistry*, 62 (17), 7788–7805. doi: <http://doi.org/10.1021/acs.jmedchem.9b00582>

Received date 10.11.2020

Accepted date 17.12.2020

Published date 30.12.2020

Sergiy Vlasov, Doctor of Pharmaceutical Sciences, Professor, Department of Organic Chemistry, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: sergiy.vlasov@gmail.com

Sergiy Kovalenko, Doctor of Chemical Sciences, Professor, Department of Organic Chemistry, V. N. Karazin Kharkiv National University, Svobody sq., 4, Kharkiv, Ukraine, 61022
E-mail: kovalenko.sergiy.m@gmail.com

Inna Orlenko, PhD, Associate Professor, Department of Organic Chemistry, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: orkoinna@ukr.net

Iryna Zhuravel, Doctor of Chemical Sciences, Professor, Head of Department, Department of Clinical Biochemistry, Forensic Toxicology and Pharmacy, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176
E-mail: irina.tox@gmail.com

Konstantin Krolenko, PhD, Scientist II, Chemical department, Ryvu Therapeutics S.A., Henryka Leona Sternbacha 2, Kraków, Poland, 30-394
E-mail: krolenko.ky@gmail.com

Vitaliy Vlasov, PhD, Associate Professor, Department of Educational and Information Technologies, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: vsv@nuph.edu.ua